A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic
About this trial
This is an interventional treatment trial for Muscular Dystrophies focused on measuring Duchenne Muscular Dystrophy, Cell Therapy, Performance of the Upper Limb, Ambulatory, Non-Ambulatory
Eligibility Criteria
Inclusion Criteria:
- Male subjects at least 10 years of age at time of consent who are willing and able to provide informed consent to participate in the trial and diagnosed with DMD as confirmed by the Investigator
- Genetically confirmed DMD
- Performance of the Upper Limb test (PUL) entry item scores 2-6 and total PUL score less than or equal to 40
- Reduced ability to walk/run (if ambulatory): subjects must take more than 10 seconds for the 10-meter walk/run (i.e., velocity < 1 meter/second)
- If non-ambulatory, loss of independent ambulation between 10th and 18th year birthday
- Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments
- Current and up-to-date immunizations
- Adequate venous access for parenteral IP infusions and routine blood collection
- Assessed by the Investigator as willing and able to comply with the requirements of the trial
- Sexually active subjects and their partners who are fertile must agree to use effective method(s) of contraception
Exclusion Criteria:
- Left ventricular ejection fraction (LVEF) less than or equal to 35% prior to randomization
- Elbow-flexion contractures > 30° in both extremities
- Body mass index (BMI) > 45
- Percent predicted forced vital capacity (FVC%) < 35% within 6 months prior to randomization
- Inability to perform consistent PUL 2.0 measurement within ± 2 points without shoulder domain or within ± 3 points with shoulder domain during paired testing at screening
- Risk of near-term respiratory decompensation in the judgment of the Investigator, or the need for initiation of day and night non-invasive ventilator support as defined by serum bicarbonate ≥ 29 mmol/L at screening
- History of non DMD-related chronic respiratory disease requiring ongoing or intermittent treatment, including, but not limited to, asthma, bronchitis, and tuberculosis
- Acute respiratory illness within 30 days prior to screening and during screening
- Initiation of nocturnal non-invasive ventilation within 30 days prior to screening
- Planned or anticipated thoracic or spinal surgery within the 6 months following randomization
- Planned or anticipated lower extremity surgery within the 6 months following randomization, if ambulatory
- Known hypersensitivity to dimethyl sulfoxide (DMSO) or bovine products
- Initiation of treatment with metformin or insulin within 3 months prior to randomization
- Initiation of treatment with an FDA-approved exon skipping therapy for the treatment of DMD and/or non-weight based adjustments within 12 months prior to randomization
- Treatment with human growth hormone within 3 months prior to randomization, unless on a stable dose allowing for weight-based dose adjustments (as determined by the site Investigator) for at least 24 months prior to randomization
- Treatment with a cell therapy product within 12 months prior to randomization; any prior exposure to CAP-1002 will be excluded
- Treatment with an investigational product within 6 months prior to randomization
- History, or current use, of drugs or alcohol that could impair the ability to comply with participation in the trial
- Inability to comply with the investigational plan and follow-up visit schedule for any reason, in the judgment of the investigator
- Inability to undergo a cardiac MRI
Sites / Locations
- Arkansas Children's HospitalRecruiting
- UCSD Altman Clinical and Translational Research InstituteRecruiting
- Children's Hospital of Los Angeles, Division of NeurologyRecruiting
- University of California, DavisRecruiting
- Children's Hospital ColoradoRecruiting
- Rare Disease Research, LLCRecruiting
- University of Iowa Hospitals and ClinicsRecruiting
- Boston Children's HospitalRecruiting
- University of Missouri Health CareRecruiting
- Saint Louis Children's HospitalRecruiting
- Akron Children's HospitalRecruiting
- Cincinnati Children's Hospital Medical CenterRecruiting
- Children's Health Specialty Care PavilionRecruiting
- University of Utah HospitalRecruiting
- University of Virginia Children's HospitalRecruiting
- Seattle Children'sRecruiting
- Children's WisconsinRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
CAP-1002
Placebo
Cohort A: Approximatetly 29 subjects will receive CAP-1002A active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months Cohort B: Approximately 22 participants will receive CAP-1002B active treatment consisting of 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months
Cohort A: Approximately 29 subjects will receive a Placebo solution via intravenous infusion every 3 months Cohort B: Approximately 22 participants will receive a Placebo solution via intravenous infusion every 3 months